1-20 of 32
Yaël P. Mossé
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 7041: The CLK/DYRK inhibitor SM09419 shows potent efficacy across a broad panel of pediatric preclinical xenograft models - A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)

Free
Richard B. Lock, Raushan Kurmasheva, Kathryn Evans, David Groff, Ben Watts, Kateryna Krytska, Christopher M. Smith, Faith N. Key, Daniella Cofini, Miguel Agoncillo, Steven Neuhauser, Timothy M. Stearns, Emily L. Jocoy, Jee Young Kwon, Jeffrey H. Chuang, Beverly A. Teicher, Richard Gorlick, Yael P. Mossé, John M. Maris, Peter J. Houghton, Carol J. Bult, Malcolm A. Smith
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7041.
https://doi.org/10.1158/1538-7445.AM2025-7041
Published: 21 April 2025
View articletitled, Abstract 7041: The CLK/DYRK inhibitor SM09419 shows potent efficacy across a broad panel of pediatric preclinical xenograft models - A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)
Journal Articles

Abstract 7040: The B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) Consortium

Free
Haiying Tang, Edward Favours, Samson Ghilu, Peyton Wong, Vanessa Del Pozo, Abhik Bandyopadhyay, Elena Mironova, Eric J. Earley, Stephen W. Erickson, David Groff, Beverly A. Teicher, Kateryna Krytska, Matthew Tsang, Yael P. Mosse, E. Anders Kolb, Matthew Stephens, Steve Neuhauser, Tim Stearns, Jeff Chuang, Emily L. Jocoy, Jee Young Kwon, Carol Bult, Malcolm A. Smith, John M. Maris, Richard G. Gorlick, Peter J. Houghton, Raushan Kurmasheva
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7040.
https://doi.org/10.1158/1538-7445.AM2025-7040
Published: 21 April 2025
View articletitled, Abstract 7040: The B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) Consortium
Journal Articles

Abstract 1201: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models

Free
Minu Samanta, Daivd Groff, Isabel Soria-Bretones, Joanna Li, Parham Nejad, Elliot Goodfellow, Alvin Farrel, Khushbu Patel, Kateryna Krytska, Steven B. Neuhauser, Timothy M. Stearns, Yael P. Mossé, JD Schonhoft, Marc L. Hyer, Michal Zimmermann, Gary Marshall, John M. Maris
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 1201.
https://doi.org/10.1158/1538-7445.AM2025-1201
Published: 21 April 2025
View articletitled, Abstract 1201: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models
Journal Articles

Abstract 6379: Identification of selective, orally bioavailable aurora A degraders for treatment of pediatric and adult cancers

Free
Hua Tian, Eric Wegrzyniak, Ya-Wen Lu, Jeffrey T. Mihalic, Ryan Rountree, Tina Acholla, Bikash Adhikari, Karthik Arumugam, Paul Auger, Graham Carlson, Robert Cass, Coleen E. Casey, Abhinav Chaterjee, Lorenz Eing, James Iuliano, Adrienne Le, Yifan Li, Victoria Louie, Filippo Marchioni, Daniel Medina-Cleghorn, Isabel Morgado, Michael Mormino, Madeleine Nemchek, Erick Palomares, Rusha Sardhara, Julie Sheung, Sangita Sridharan, Gintvile Valinciute, Dipna Venkatachalam, Simon Vezina-Dawod, Derek Wodka, Stephanie Yung, Martin Eilers, John M. Maris, Yael P. Mossé, Martine F. Roussel, Elmar Wolf, Gwenn M. Hansen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 6379.
https://doi.org/10.1158/1538-7445.AM2025-6379
Published: 21 April 2025
View articletitled, Abstract 6379: Identification of selective, orally bioavailable aurora A degraders for treatment of pediatric and adult cancers
Journal Articles

Abstract 3357: Identifying mechanisms of acquired resistance to lorlatinib utilizing a genome-wide CRISPR-Cas9 screen

Free
Joshua Renn Kalna, Smita Matkar, Emily O'Drisoll, Skye Balyasny, Matteo Calafatti, Mark Gerelus, Dave Groff, Tina Acholla, Colleen E. Casey, Paul Kamitsuka, Grant Li, Steven J. Pastor, Gabriela Witek, Kateryna Krytska, Jarrett Lindsay, Ophir Shalem, Yael P. Mossé
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3357.
https://doi.org/10.1158/1538-7445.AM2024-3357
Published: 22 March 2024
View articletitled, Abstract 3357: Identifying mechanisms of acquired resistance to lorlatinib utilizing a genome-wide CRISPR-Cas9 screen
Journal Articles

Abstract 4515: PIONEER: harnessing multi-omics data to enhance immunotherapeutic target discovery and development

Free
Amber K. Weiner, Hemma Murali, Rawan Shraim, Karina L. Conkrite, Alexander B. Radaoui, Daniel Martinez, Brian Mooney, Sandra E. Spencer Miko, Gian Negri, Alberto Delaidelli, Caitlyn de Jong, Yuankun Zhu, Allison P. Heath, Jennifer Pogoriler, Yael P. Mosse, Deanne M. Taylor, Poul H. Sorensen, Gregg B. Morin, Benjamin A. Garcia, John M. Maris, Sharon J. Diskin
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4515.
https://doi.org/10.1158/1538-7445.AM2023-4515
Published: 04 April 2023
View articletitled, Abstract 4515: PIONEER: harnessing multi-omics data to enhance immunotherapeutic target discovery and development
Journal Articles

Abstract 2006: Preclinical evaluation of dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition in neuroblastoma (NB)

Free
David Groff, Colleen Casey, Kateryna krytska, Matthew Tsang, Christina Acholla, John M. Maris, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2006.
https://doi.org/10.1158/1538-7445.AM2022-2006
Published: 15 June 2022
View articletitled, Abstract 2006: Preclinical evaluation of dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition in neuroblastoma (NB)
Journal Articles

Abstract 2012: A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate (ADC) demonstrates potent cytotoxicity in neuroblastoma (NBL) and fusion positive rhabdomyosarcoma (FP RMS)

Free
Alberto D. Guerra, Annie Kennedy, Cynthia Adams, Rawan Shraim, Amber K. Weiner, Chuan Chen, Kateryna Krytska, Colleen Larmour, Smita Matkar, Dimiter Dimitrov, Dontcho V. Jelev, Yael P. Mossé
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2012.
https://doi.org/10.1158/1538-7445.AM2022-2012
Published: 15 June 2022
View articletitled, Abstract 2012: A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate (ADC) demonstrates potent cytotoxicity in neuroblastoma (NBL) and fusion positive rhabdomyosarcoma (FP RMS)
Journal Articles

Abstract 699: NF-kB is a master regulator of resistance to therapy in high-risk neuroblastoma

Free
Liron D. Grossmann, Yasin Uzun, Jarrett Lindsay, Chia-Hui Chen, Catherine Wingrove, Peng Gao, Anusha Thadi, Quinlen Marshall, Nathan M. Kendsersky, Lea Surrey, Daniel Martinez, Emily Mycek, Colleen Casey, Kateryna Krytska, Matthew Tsang, Adam Wolpaw, David N. Groff, Erin Runbeck, Jayne McDevitt, Dinh Diep, Tasleema Patel, Kathrin M. Bernt, Chi Dang, Kun Zhang, Yael P. Mosse, Kai Tan, John M. Maris
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 699.
https://doi.org/10.1158/1538-7445.AM2022-699
Published: 15 June 2022
View articletitled, Abstract 699: NF-kB is a master regulator of resistance to therapy in high-risk neuroblastoma
Journal Articles

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

Free
Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn H. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Levens, John M. Maris, Ronen Marmorstein, Steven J. Metallo, Julie R. Park, Linda Z. Penn, Michael Rape, Martine F. Roussel, Kevan M. Shokat, William P. Tansey, Kliment A. Verba, Seychelle M. Vos, William A. Weiss, Elmar Wolf, Yaël P. Mossé
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (7): 1627–1632.
https://doi.org/10.1158/0008-5472.CAN-20-3108
Published: 01 April 2021
View articletitled, Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Open the PDF for Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers in another window
Journal Articles

Abstract 3105: Serial profiling of ctDNA identifies clinically actionable genomic evolution in high-risk neuroblastoma

Free
Kristopher R. Bosse, Samantha Buongervino, Maria Lane, Adam Hyman, Maria Gemino-borromeo, Jennifer Saggio, Alana Fitzsimmons, Brady Forcier, Anne Murphy, John Wick, Matthew Cooke, Jennifer Webster, Russell Madison, Alley Welsh, Vincent A. Miller, Siraj M. Ali, John M. Maris, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3105.
https://doi.org/10.1158/1538-7445.AM2019-3105
Published: 01 July 2019
View articletitled, Abstract 3105: Serial profiling of ctDNA identifies clinically actionable genomic evolution in high-risk neuroblastoma
Journal Articles

Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma

Free
Renata Sano, Kateryna Krytska, Matthew Tsang, Stephen W. Erickson, Beverly A. Teicher, Laura Saunders, Ryan T. Jones, Malcom A. Smith, John M. Maris, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-136.
https://doi.org/10.1158/1538-7445.AM2018-LB-136
Published: 01 July 2018
View articletitled, Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma
Journal Articles

Abstract 1633: Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas

Free
Smita Matkar, Renata Sano, Colleen Larmour, Kateryna Krytska, Gabriela M. Witek, Mark Gerelus, Tim J. Stuhlmiller, Gary L. Johnson, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1633.
https://doi.org/10.1158/1538-7445.AM2018-1633
Published: 01 July 2018
View articletitled, Abstract 1633: Chemical proteomics identifies druggable proteins in ALK-driven neuroblastomas
Journal Articles

Abstract 3000: Defining the subclonal landscape of high-risk neuroblastoma

Free
Jo Lynne Harenza, Maura A. Diamond, Derek A. Oldridge, Olivia Padovan-Merher, Pichai Raman, Yael P. Mosse, John M. Maris
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3000.
https://doi.org/10.1158/1538-7445.AM2017-3000
Published: 01 July 2017
View articletitled, Abstract 3000: Defining the subclonal landscape of high-risk neuroblastoma
Journal Articles

Abstract 2431: Enrichment of targetable mutations in the relapsed neuroblastoma genome

Free
Olivia M. Padovan-Merhar, Pichai Raman, Kaitlyn R. Rubnitz, Siraj M. Ali, Vincent A. Miller, Yael P. Mosse, Meaghan P. Granger, Brian D. Weiss, John M. Maris, Shakeel Modak
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2431.
https://doi.org/10.1158/1538-7445.AM2016-2431
Published: 15 July 2016
View articletitled, Abstract 2431: Enrichment of targetable mutations in the relapsed neuroblastoma genome
Journal Articles

Abstract 2690: A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma

Free
Renata Sano, Kateryna Krytska, Colleen Larmour, Gwenda F. Ligon, Jay S. Lillquist, Ulisse Cucchi, Paolo Orsini, Simona Rizzi, Gerald McMahon, Diego Alvarado, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2690.
https://doi.org/10.1158/1538-7445.AM2016-2690
Published: 15 July 2016
View articletitled, Abstract 2690: A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma
Journal Articles

Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma

Free
Nicole Infarinato, Jin Park, Renata Sano, Kateryna Krytska, Hannah Ryles, Helen Zou, Nathan Lee, Tod Smeal, Mark A. Lemmon, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1619.
https://doi.org/10.1158/1538-7445.AM2015-1619
Published: 01 August 2015
View articletitled, Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma
Journal Articles

Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity

Available to Purchase
Kristopher R. Bosse, Sharon J. Diskin, Kristina A. Cole, Andrew C. Wood, Robert W. Schnepp, Geoffrey Norris, Le B. Nguyen, Jayanti Jagannathan, Michael Laquaglia, Cynthia Winter, Maura Diamond, Cuiping Hou, Edward F. Attiyeh, Yael P. Mosse, Vanessa Pineros, Eva Dizin, Yongqiang Zhang, Shahab Asgharzadeh, Robert C. Seeger, Mario Capasso, Bruce R. Pawel, Marcella Devoto, Hakon Hakonarson, Eric F. Rappaport, Irmgard Irminger-Finger, John M. Maris
Journal: Cancer Research
Cancer Res (2012) 72 (8): 2068–2078.
https://doi.org/10.1158/0008-5472.CAN-11-3703
Published: 16 April 2012
View articletitled, Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity
Open the PDF for Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity in another window
Includes: Supplementary data
Journal Articles

Abstract 742: Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma

Free
Erica L. Carpenter, Elizabeth A. Haglund, Adrian K. Chow, James G. Christensen, John M. Maris, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 742.
https://doi.org/10.1158/1538-7445.AM2011-742
Published: 15 April 2011
View articletitled, Abstract 742: Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma
Journal Articles

Abstract 926: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma

Free
Olena Morozova, Inanc Birol, Richard Corbett, Karen Mungall, Edward F. Attiyeh, Shahab Asgharzadeh, Yongjun Zhao, Richard A. Moore, Martin Hirst, Steven Jones, Michael D. Hogarty, Sharon Diskin, Yael P. Mosse, Maura Diamond, Richard Sposto, Lingyun Ji, Daniela S. Gerhard, Malcolm A. Smith, Javed Khan, Robert C. Seeger, Marco A. Marra, John M. Maris, NCI TARGET Initiative
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 926.
https://doi.org/10.1158/1538-7445.AM2011-926
Published: 15 April 2011
View articletitled, Abstract 926: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma